Chemotherapy for metastatic basal cell carcinoma

Abstract

Metastatic basal cell carcinoma is a rare, malignant neoplasm associated with poor survival. A 63-year-old woman had an extensive primary keratinizing basal cell carcinoma of the scalp, with metastases to the regional lymph nodes of the neck. Disease in the primary site and in the regional lymph nodes was controlled by surgery and irradiation. However, skeletal metastases that responded to therapy with three courses of cisplatin and bleomycin sulfate and then to ten courses of cyclophosphamide, methotrexate, and fluorouracil developed. Subsequent progressive metastases failed to respond to a combined cisplatin and cyclophosphamide regimen as well as to etoposide and doxorubicin hydrochloride used as single agents.

Carcinoma basocelular metastásico en la región parotídea: un nuevo caso

“…Por otro lado las metástasis en pulmón, hueso y tejidos blandos que sean irresecables, pueden ser tratadas con quimioterapia. Actualmente la experiencia con quimioterapia se reduce a escasos estudios con series reducidas; se han utilizado con éxito varios fármacos, bien solos o de forma combinada como: cisplatino, metrotexato, ciclofosfamida, 5-fluoracilo, bleomicina, vincristina y doxorrubicina (24). Pfeiffer et al presentan una serie sobre terapia citotóxica sistémica y carcinoma basocelular en la que demuestran que el cisplatino es el agente más efectivo, con una supervivencia media mayor a la obtenida con otros fármacos (25).…”

Recurrent Periocular Basal Cell Carcinoma. Case Report

“…Centrálna zraková ostrosť bez svetlocitu. Horná mihalnica je deformovaná, prítomné sú tuhé rezistencie s ulcerovaným povrchom, dĺžky do 20…”

“…Lokálna farmakologická liečba, vrátane imunomodulátora imiquimod, je menej úspešná a v lokalizácii v blízkosti okraja mihalnice, vonkajšieho alebo vnútorného kútika sa ešte v širšom meradle nevyužíva [19]. V minulosti aplikovaná i chemoterapia pri liečbe BCC, no neúspešne [20].…”

A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors

“…Investigator-assessed response rates were 60.3% for laBCC and 48.5% for mBCC with vismodegib [12] and 71.2% for laBCC with sonidegib [13]. Given the rarity of mBCC (<0.1%) 1 , there are only limited reports of chemotherapy for patients with mBCC with transient or disappointing results or intolerable toxicity [14][15][16][17]. For mBCC, the median progression-free survival (PFS), with vismodegib at approved dosing, was 9.3 months in the ERIVANCE study [12] and 13.1 months in the STEVIE study [18], and with sonidegib was 13.1 months in the BOLT study [13].…”